Home > Boards > US Listed > Biotechs >

Synaptogenix Inc. (SNPX)

SNPX RSS Feed
Add SNPX Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, runncoach, Cyosol, Battle Ready, urge2surge
Search This Board: 
Last Post: 5/17/2022 3:48:09 PM - Followers: 112 - Board type: Free - Posts Today: 0


 

Description:
Synaptogenix (formerly known as Neurotrope) is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders. For more information, visit: https://www.synaptogen.com/

Market Information (as of April 14, 2022):
Symbol: SNPX
Stock Price: $7.03
Market Cap: $47,871,818
Outstanding Shares: 6,809,647
Outstanding Warrants & Options:

Pre-funded Warrants:
- 83,334 Pre-funded Warrants to purchase 83,334 shares of Common Stock, with an exercise price of $0.04 per share ($3,333)
- 66,251 Pre-funded Warrants to purchase 66,251 shares of Common Stock, with an exercise price of $0.01 per share ($663)

January 2021 Offering Warrants (expires April 29, 2022):
- 1,049,368 Series E Warrants to purchase 1,049,368 shares of Common Stock, with an exercise price of $8.51 per share ($8,930,122)

December 2020 Spin-off Warrants (expires December 7, 2025):
- 39,535 Series A Warrants to purchase up to 39,535 shares of Common Stock with an exercise price of $198.80 per share ($7,859,558)
- 155,917 Series B Warrants to purchase up to 155,917 shares of Common Stock with an exercise price of $79.52 per share ($12,398,520)
- 227,163 Series C Warrants to purchase up to 227,163 shares of Common Stock with an exercise price of $39.76 per share ($9,032,001)
- 555,462 Series D Warrants to purchase up to 555,462 shares of Common Stock with an exercise price of $15.92 per share ($8,842,955)

January 2021 Offering Warrants (expires January 25, 2026):
- 2,029,179 Series F Warrants to purchase up to 2,029,179 shares of Common Stock with an exercise price of $6.90 per share ($14,001,335)
 
January 2021 Offering Warrants (expires January 29, 2026):
- 206,057 Placement Agent Warrants to purchase up to 206,057 shares of Common Stock with an exercise price of $6.90 per share ($1,421,793)

Consulting Warrants (expires February 16, 2026):
- 35,000 Consulting Warrants to purchase up to 35,000 shares of Common Stock with an exercise price of $11.46 per share ($401,100)
 
Consulting Warrants (expires April 1, 2026):
- 7,000 Consulting Warrants to purchase up to 7,000 shares of Common Stock with an exercise price of $8.80 per share ($61,600)

June 2021 Offering Warrants (expires June 16, 2026):
- 1,573,281 Series G Warrants to purchase up to 1,573,281 shares of Common Stock with an exercise price of $8.51 per share ($13,388,621)
- 152,378 Placement Agent Warrants to purchase up to 152,378 shares of Common Stock with an exercise price of $8.51 per share ($1,296,737)

Consulting Warrants (expires July 1, 2026):
- 10,300 Consulting Warrants to purchase up to 10,300 shares of Common Stock with an exercise price of $9.76 per share ($100,528)

Consulting Warrants (expires October 1, 2026):
- 10,300 Consulting Warrants to purchase up to 10,300 shares of Common Stock with an exercise price of $9.30 per share ($95,790)

Consulting Warrants (expires January 3, 2027):
- 10,300 Consulting Warrants to purchase up to 10,300 shares of Common Stock with an exercise price of $8.69 per share ($89,507)
 
Options:
- 123,850 Options to purchase up to 123,850 shares of Common Stock with a weighted-average exercise price of $9.84 per share ($1,218,684)
 
To be raised from exercised warrants & options: $79,142,847
Fully diluted shares (Outstanding Shares + Warrants + Options): 13,144,322
Fully diluted market cap: $92,404,584

Reports:
Roth report (2018): https://pdfhost.io/v/i@2x9BB+F_37943455120180308NTRPRothInitpdf.pdf
Maxim report (2018): https://pdfhost.io/v/agpp@2Q+o_379427337NTRPinitiationpdf.pdf
Janney report (2019): https://pdfhost.io/v/iQV43NGcT_413879072NTRPInitiation06182019pdf.pdf

Press Releases:
Phase 2a results (2015): https://www.prnewswire.com/news-releases/neurotrope-announces-positive-top-line-results-from-its-phase-2a-study-of-bryostatin-1-in-alzheimers-disease-300038367.html

Exploratory Phase 2b results (2017): https://www.prnewswire.com/news-releases/neurotrope-announces-positive-top-line-results-from-phase-2-study-of-bryostatin-1-for-moderate-to-severe-alzheimers-disease-300448563.html
Exploratory Phase 2b analysis (2018): https://www.prnewswire.com/news-releases/neurotropes-bryostatin-improves-cognition-in-patients-with-advanced-alzheimers-disease-based-on-further-analysis-of-phase-2-clinical-trial-data-300578025.html

Confirmatory Phase 2b results (2019): https://www.prnewswire.com/news-releases/neurotrope-announces-top-line-results-from-confirmatory-phase-2-study-of-bryostatin-1-in-moderate-to-severe-alzheimers-disease-300913655.html
Confirmatory Phase 2b analysis (2020): https://www.prnewswire.com/news-releases/neurotrope-provides-corporate-update-after-completing-bryostatin-1-data-analysis-for-advanced-alzheimers-disease-trial-300991105.html

Scientific Articles:
[P2a & CU results] "Bryostatin Effects on Cognitive Function and PKC epsilon in Alzheimer’s Disease Phase IIa and Expanded Access Trials" (2017): https://pdfhost.io/v/XAcILs@Hc_jad2F20172F5822Fjad582jad1701612Fjad58jad170161pdf.pdf
[Exploratory P2b results] "A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Ef?cacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s Disease" (2018): https://pdfhost.io/v/GEa58CPiF_farlow2018pdf.pdf
[Memantine results] "Memantine in Moderate-to-Severe Alzheimer's Disease" (2003): https://www.nejm.org/doi/full/10.1056/NEJMoa013128
More scientific articles: https://pdfhost.io/v/.~Rt1cU63_bryo1.pdf

Patents:
Patents by Daniel L. Alkon: https://patents.justia.com/inventor/daniel-l-alkon
Patents by Daniel L. Alkon (grants only): http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&p=1&f=S&l=50&Query=IN%2FAlkon-Daniel-L.&d=PTXT
Patents by Daniel L. Alkon (applications only): http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=0&p=1&f=S&l=50&Query=IN%2FAlkon-Daniel-L&d=PG01

Media:
"A new era for treating diseases of the brain" (2008): https://youtu.be/W1pdg1kvQHI
"Rockefeller Institute drug provides hope for Alzheimer’s treatment" (2015): https://www.wvgazettemail.com/news/rockefeller-institute-drug-provides-hope-for-alzheimer-s-treatment/article_bf5bab5f-e40e-5f47-95ca-666f14b795e0.html
"The Scoop: Alzheimer’s Drug Tries to Build Up a Head of Steam" (2018): https://www.genengnews.com/magazine/the-scoop-alzheimers-drug-tries-to-build-up-a-head-of-steam/
"Advancements in Alzheimer’s Treatment: Interview with Dr. Daniel Alkon" (2018): https://newyork.legalexaminer.com/health/senior-care/advancements-in-alzheimers-treatment-interview-with-dr-daniel-alkon/
"Company Seeks to Prove Marine-Derived Alzheimer's Drug Is No Fish Story" (2019): https://soundcloud.com/levine-media-group/company-seeks-to-prove-marine-derived-alzheimers-drug-is-no-fish-story
"Pizza Hut co-founder’s compassionate-care Alzheimer’s trial leads to hope for others" (2019): https://www.kansas.com/news/business/biz-columns-blogs/carrie-rengers/article229253744.html
"After A Big Failure, Scientists And Patients Hunt For A New Type Of Alzheimer's Drug" (2019): https://www.npr.org/sections/health-shots/2019/05/03/718754791/after-a-big-failure-scientists-and-patients-hunt-for-a-new-type-of-alzheimers-d
Dr. Alkon at Alzheimer's Solutions Conference (2019): https://www.youtube.com/watch?v=bP5GcAplXls
How an Alzheimer’s ‘cabal’ thwarted progress toward a cure (2019): https://www.statnews.com/2019/06/25/alzheimers-cabal-thwarted-progress-toward-cure/
Charles Ryan On Treating Alzheimer's Disease (2019): https://tdameritradenetwork.com/video/rB4AoWt8Hk2Ba5865CUHvQ
The Impacts of Alzheimer's Disease are Growing (2019): https://www.youtube.com/watch?v=x4NkJqASGZc
Synaptogenix | Investor Presentation | Benzinga Global Small Cap Conference (2021): https://youtu.be/XW6p2kImbvM
Company Overview: Synaptogenix (SNPX) - Possible New Alzheimer's Treatment (2021): https://tdameritradenetwork.com/video/rB4A-HpDFiiBekSTg3kAXQ
Synaptogenix | Benzinga Healthcare Small Cap Conference (2021): https://www.youtube.com/watch?v=O_UifVfRgfM

Links:
Investor relations: https://www.synaptogen.com/ir/
SEC filings:
- Neurotrope Inc: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001513856
- Synaptogenix Inc: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001571934
Alzheimer's disease drug development pipeline 2021: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145448/
Bryostatin vs. Memantine vs. Placebo comparison: https://i.imgur.com/579PX0L.jpg
Test comparison: https://i.imgur.com/s61opUd.jpg
BryoLogyx: https://bryologyx.com/
NeuroDiagnostics: https://www.ndx-discern.com/
Ongoing trial: https://clinicaltrials.gov/ct2/show/NCT04538066
Institutional Ownership: https://fintel.io/so/us/snpx
Short Interest Data: https://www.shortablestocks.com/?SNPX
Stocktwits: https://stocktwits.com/symbol/SNPX

SNPX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#17218  Sticky Note Quick summary for those that are new: Cyosol 05/25/21 02:44:41 PM
#16239  Sticky Note Neurotrope is a front for old money and XenaLives 08/29/20 06:05:05 AM
#16205  Sticky Note FDA trial results. Includes Statistical plan and trial runncoach 07/08/20 08:25:53 PM
#19525   Oh wow, thanks Vivid. novicetrader 05/17/22 03:48:09 PM
#19524   yes VividC 05/17/22 03:40:04 PM
#19523   is this from today's presentation? novicetrader 05/17/22 03:36:20 PM
#19522   will do, thanks! VividC 05/17/22 02:54:00 PM
#19521   If you google (or search on ihub even) runncoach 05/17/22 02:36:20 PM
#19520   did not know that background. In my view VividC 05/17/22 02:04:11 PM
#19519   Thanks Vivid. runncoach 05/17/22 01:55:46 PM
#19518   here the abstract: https://app.oxfordabstracts.com/events/1565/submissions/33089 VividC 05/17/22 01:09:05 PM
#19517   like this one: "Through direct regulation of the VividC 05/17/22 10:31:36 AM
#19516   https://ir.synaptogen.com/news-releases/ Alzy B 05/17/22 09:29:08 AM
#19515   Hopefully they wait until topline data is out Cyosol 05/15/22 04:56:48 PM
#19514   You can find the latest warrant info in Cyosol 05/15/22 04:49:28 PM
#19513   Yes. Not many in Q1. It was runncoach 05/15/22 02:58:04 PM
#19512   Coach, remember you saying the quarterly will show novicetrader 05/15/22 02:46:49 PM
#19509   - financials in good shape, cash burn at VividC 05/13/22 05:20:33 PM
#19508   Couple things I don't remember from the 10k, runncoach 05/13/22 04:45:39 PM
#19507   It's out now. Haven't read it yet runncoach 05/13/22 04:36:42 PM
#19506   well that was a positive trading day. With VividC 05/13/22 04:23:18 PM
#19505   Cyosol, thanks for the reply. Theburg 05/13/22 12:07:26 PM
#19504   They'll probably just throw out a PR like Cyosol 05/13/22 04:12:58 AM
#19503   The top line data will include the primary Theburg 05/12/22 07:02:42 PM
#19502   It tends to follow the NBI which was Cyosol 05/12/22 05:57:53 PM
#19501   I day reprieve? Heck, I'll take it. runncoach 05/12/22 04:25:01 PM
#19500   Are my eyes deceiving me, or did SNPX Battle Ready 05/12/22 04:07:05 PM
#19499   Thanks for this.Was really hoping there was more novicetrader 05/12/22 08:37:53 AM
#19498   Thanks for the info runncoach 05/12/22 07:47:04 AM
#19497   The USPTO will publish a patent application on Investor2014 05/12/22 05:55:00 AM
#19496   I do like that idea better! Maybe Battle Ready 05/11/22 07:54:22 PM
#19495   No,BR.I didn't mean company buyback of shares(they need novicetrader 05/11/22 07:37:15 PM
#19494   I'm thinking that a positive trial result will Battle Ready 05/11/22 07:04:54 PM
#19493   Topline data is this year but full data Cyosol 05/11/22 05:51:13 PM
#19492   Great idea on the company officers buying shares, Battle Ready 05/11/22 05:21:31 PM
#19491   They would almost have to double the share runncoach 05/11/22 05:19:15 PM
#19490   Completely agree RC!!! Plenty of cash to Battle Ready 05/11/22 04:48:27 PM
#19489   Cyosol, with $35 million in cash on 12/31/21, Battle Ready 05/11/22 04:43:30 PM
#19488   Agree. I would rather go down and runncoach 05/11/22 04:43:06 PM
#19487   The old saying when times are bad buy Whoopddew 05/11/22 04:37:12 PM
#19486   Won't be a problem if management does the Cyosol 05/11/22 04:17:29 PM
#19485   They only have enough cash to finish the Cyosol 05/11/22 04:14:01 PM
#19484   At this price will be below 0 in runncoach 05/11/22 04:08:39 PM
#19483   The price makes more sense once you look Cyosol 05/11/22 04:07:52 PM
#19482   By the end of the week, yes. runncoach 05/11/22 03:00:39 PM
#19481   The 10Q should be out any day now?? Battle Ready 05/11/22 02:58:23 PM
#19480   Great idea! There is plenty of cash, Battle Ready 05/11/22 02:53:48 PM
#19479   same here,went against my better judgement and added novicetrader 05/11/22 02:23:32 PM
#19478   Swore I wouldn't do it but added 5% runncoach 05/11/22 02:13:53 PM
#19477   Looks l like the 1-year warrants expired since runncoach 05/11/22 02:08:19 PM
#19476   There is NO negative news on SNPX, in Battle Ready 05/11/22 01:59:00 PM
#19475   And 3.97 prints. Good grief runncoach 05/11/22 01:51:12 PM
#19474   Yeah, this stock is just following the index. Cyosol 05/11/22 01:48:54 PM
PostSubject
Consent Preferences